With a local approval in hand, India's Aurobindo is moving forward with its plans for a major expansion of its U.S. manufacturing operations.
Local authorities in East Windsor, NJ, have given the thumbs up to Aurobindo to build a 567,000-square-foot manufacturing, warehouse and distribution facility, NJ.com reported. The company has said that it might eventually need 400 to 500 workers for the operation. The move comes as Aurobindo is expecting to significantly boost its business in the U.S. It has said that it has about 45 generic drug applications pending before the FDA.
It is the second Indian drugmaker to announce big manufacturing plans for the U.S. in recent weeks. Cipla last month announced it was buying InvaGen Pharmaceuticals and a related company for $550 million. The acquisition will give Cipla its first U.S. manufacturing operation, a 350,000 square-foot facility in Hauppauge, NY, with an annual production capacity of 12 billion tablets and capsules.
Aurobindo has been on an expansion binge in India as well. Earlier in the month it said it was investing 300 crore rupees ($46.3 million) to increase the capacity of an API plant in Telangana, India. In August, Aurobindo reported it intended to invest about 900 crore rupees ($137 million) next year toward three new plants. That is to include work on an oral solid finished dosages facility at Naidupeta, an oral finished dosage facility in Visakhapatnam, and a semisynthetic penicillin plant at Jadcherla, near Hyderabad.
- read the NJ.com story